{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:56:19Z","timestamp":1792065379330,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development & Commercialization Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013327","name":"H Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032121","name":"Lundbeck USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jad.2026.122190","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:44:44Z","timestamp":1782888284000},"page":"122190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed"],"prefix":"10.1016","volume":"413","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Hutson Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Norman","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karimah S.","family":"Bell Lynum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jad.2026.122190_bb0005","doi-asserted-by":"crossref","first-page":"791","DOI":"10.4103\/ijcm.ijcm_601_23","article-title":"Statistical significance versus clinical relevance: key considerations in interpretation medical research data","volume":"49","author":"AbdulRaheem","year":"2024","journal-title":"Indian J. Community Med."},{"key":"10.1016\/j.jad.2026.122190_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision","author":"American Psychiatric Association","year":"2022"},{"issue":"1","key":"10.1016\/j.jad.2026.122190_bb0015","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.4088\/JCP.16f11380","article-title":"Likelihood of being helped or harmed as a measure of clinical outcomes in psychopharmacology","volume":"78","author":"Andrade","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2026.122190_bb0020","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.biopsych.2004.09.022","article-title":"Mood state at study entry as predictor of the polarity of relapse in bipolar disorder","volume":"56","author":"Calabrese","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122190_bb0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4088\/JCP.16m11201","article-title":"Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: double-blind, placebo-controlled, 52-week randomized withdrawal study","volume":"78","author":"Calabrese","year":"2017","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2026.122190_bb0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40345-018-0122-z","article-title":"Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study","volume":"6","author":"Calabrese","year":"2018","journal-title":"Int. J. Bipolar Disord."},{"issue":"6","key":"10.1016\/j.jad.2026.122190_bb0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.jad.2026.122190_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0447.2009.01449.x","article-title":"Relative vs. absolute measures of benefit and risk: what\u2019s the difference?","volume":"121","author":"Citrome","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"5\u20136","key":"10.1016\/j.jad.2026.122190_bb0045","first-page":"26","article-title":"Quantifying clinical relevance","volume":"11","author":"Citrome","year":"2014","journal-title":"Innov. Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.jad.2026.122190_bb0050","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1017\/S1092852921000249","article-title":"Long-acting injectable antipsychotics: what, when, and how","volume":"26","author":"Citrome","year":"2021","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.jad.2026.122190_bb0055","doi-asserted-by":"crossref","DOI":"10.1017\/S109285292510059X","article-title":"Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide","volume":"30","author":"Citrome","year":"2025","journal-title":"CNS Spectr."},{"issue":"7","key":"10.1016\/j.jad.2026.122190_bb0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert Rev. Neurother."},{"issue":"5","key":"10.1016\/j.jad.2026.122190_bb0065","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2026.122190_bb0070","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13795","article-title":"Lemborexant for the treatment of insomnia: direct and indirect comparisons with other hypnotics using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"82","author":"Citrome","year":"2021","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2026.122190_bb0075","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1007\/s12325-021-01848-x","article-title":"Benefit-risk assessment of galcanezumab versus placebo for the treatment of episodic and chronic migraine using the metrics of number needed to treat and number needed to harm","volume":"38","author":"Citrome","year":"2021","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.jad.2026.122190_bb0080","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.26m16359","article-title":"Aripiprazole once-monthly for patients diagnosed with schizophrenia: number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"87","author":"Citrome","year":"2026","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.122190_bb0085","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s12264-014-1534-0","article-title":"Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat","volume":"31","author":"Gao","year":"2015","journal-title":"Neurosci. Bull."},{"issue":"4","key":"10.1016\/j.jad.2026.122190_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40263-023-00996-8","article-title":"A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder","volume":"37","author":"Harlin","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2026.122190_bb0095","series-title":"Risperdal Consta (risperidone). Prescribing information","author":"Janssen Pharmaceuticals, I","year":"2025"},{"issue":"11","key":"10.1016\/j.jad.2026.122190_bb0100","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4088\/JCP.14m09168","article-title":"Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study","volume":"75","author":"Kane","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.122190_bb0105","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","article-title":"A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder","volume":"67","author":"Keck","year":"2006","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.jad.2026.122190_bb0110","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.4088\/JCP.v68n1003","article-title":"Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo","volume":"68","author":"Keck","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2026.122190_bb0115","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1038\/s41380-020-00946-6","article-title":"Mood stabilizers and\/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials","volume":"26","author":"Kishi","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"15","key":"10.1016\/j.jad.2026.122190_bb0120","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1017\/S0033291720003505","article-title":"Recurrence rates in stable bipolar disorder patients after drug discontinuation v. drug maintenance: a systematic review and meta-analysis","volume":"51","author":"Kishi","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2026.122190_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115761","article-title":"A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: a systematic review","volume":"333","author":"Kishi","year":"2024","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.jad.2026.122190_bb0130","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/03007995.2023.2219155","article-title":"Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study","volume":"39","author":"McIntyre","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2026.122190_bb0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.122190_bb0140","series-title":"Abilify Asimtufii (aripiprazole) prescribing information","author":"Otsuka America Pharmaceutical, Inc.","year":"2025"},{"key":"10.1016\/j.jad.2026.122190_bb0145","series-title":"Abilify Maintena\u00ae (aripiprazole). Prescribing information","author":"Otsuka America Pharmaceutical, Inc.","year":"2025"},{"key":"10.1016\/j.jad.2026.122190_bb0150","series-title":"Rykindo (risperidone). Prescribing information","author":"Shandong Luye Pharmaceutical Co., Ltd.","year":"2025"},{"issue":"4","key":"10.1016\/j.jad.2026.122190_bb0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4103\/sja.sja_158_21","article-title":"Statistical significance or clinical significance? A researcher's dilemma for appropriate interpretation of research results","volume":"15","author":"Sharma","year":"2021","journal-title":"Saudi J Anaesth"},{"issue":"Suppl. 20","key":"10.1016\/j.jad.2026.122190_bb0160","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.122190_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.jad.2026.122190_bb0170","first-page":"210","article-title":"Individualizing treatment decisions. The likelihood of being helped or harmed","volume":"25","author":"Straus","year":"2002","journal-title":"Eval. Health Prof."},{"key":"10.1016\/j.jad.2026.122190_bb0175","series-title":"UZEDY (Risperidone) Extended-Release Injectable Suspension, for Subcutaneous Use. (Highlights of prescribing information)","author":"Teva Neuroscience Inc.","year":"2025"},{"issue":"5","key":"10.1016\/j.jad.2026.122190_bb0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1177\/0333102418801579","article-title":"Benefit-risk assessment of erenumab and current migraine prophylactic treatments using the likelihood of being helped or harmed","volume":"39","author":"Vo","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jad.2026.122190_bb0185","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jad.2024.01.257","article-title":"Preventive effect of aripiprazole once-monthly on relapse into mood episodes in bipolar disorder: a multicenter, one-year, retrospective, mirror image study","volume":"351","author":"Woo","year":"2024","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2026.122190_bb0190","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0165-0327(11)70005-2","article-title":"A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder","volume":"128","author":"Yatham","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122190_bb0195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"updated-by":[{"DOI":"10.1016\/j.jad.2026.122470","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000}}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726010426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726010426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:44:05Z","timestamp":1787381045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726010426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S0165032726010426"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122190","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aripiprazole once-monthly for patients diagnosed with bipolar I disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"122190"}}